Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

被引：0
|
作者：
Ke Xu
Dongkyoo Park
Andrew T. Magis
Jun Zhang
Wei Zhou
Gabriel L. Sica
Suresh S. Ramalingam
Walter J. Curran
Xingming Deng
机构：
[1] Emory University School of Medicine and Winship Cancer Institute of Emory University,Division of Cancer Biology, Department of Radiation Oncology
[2] Institute for Systems Biology,Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Holden Comprehensive Cancer Center
[3] University of Iowa Carver College of Medicine,Department of Hematology and Medical Oncology
[4] Emory University School of Medicine and Winship Cancer Institute of Emory University,Department of Pathology and Laboratory Medicine
[5] Emory University School of Medicine and Winship Cancer Institute of Emory University,undefined
来源：
Molecular Cancer | / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
An amendment to this paper has been published and can be accessed via the original article.
引用
收藏
相关论文
共 50 条
  • [1] Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
    Xu, Ke
    Park, Dongkyoo
    Magis, Andrew T.
    Zhang, Jun
    Zhou, Wei
    Sica, Gabriel L.
    Ramalingam, Suresh S.
    Curran, Walter J.
    Deng, Xingming
    MOLECULAR CANCER, 2019, 18 (1)
  • [2] Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
    Ke Xu
    Dongkyoo Park
    Andrew T. Magis
    Jun Zhang
    Wei Zhou
    Gabriel L. Sica
    Suresh S. Ramalingam
    Walter J. Curran
    Xingming Deng
    Molecular Cancer, 18
  • [3] Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy (vol 18, 85, 2019)
    Xu, Ke
    Park, Dongkyoo
    Magis, Andrew T.
    Zhang, Jun
    Zhou, Wei
    Sica, Gabriel L.
    Ramalingam, Suresh S.
    Curran, Walter J.
    Deng, Xingming
    MOLECULAR CANCER, 2020, 19 (01)
  • [4] Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers
    Pandey, Divya
    Chauhan, Subhash C.
    Kashyap, Vivek K.
    Roy, Kuldeep K.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 277
  • [5] Selective targeting of KRAS mutant cancer cells by a novel small molecule compound
    Iskandar, Kartini
    Rezlan, Majidah
    Yadav, Sanjiv K.
    Pervaiz, Shazib
    CANCER RESEARCH, 2014, 74 (19)
  • [6] Breaking down KRAS: small-molecule degraders for cancer therapy
    Kos, Tina
    Saur, Dieter
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [7] Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
    Gillson, Josef
    Ramaswamy, Yogambha
    Singh, Gurvinder
    Gorfe, Alemayehu A.
    Pavlakis, Nick
    Samra, Jaswinder
    Mittal, Anubhav
    Sahni, Sumit
    CANCERS, 2020, 12 (05)
  • [8] A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
    Xiufeng Pang
    Mingyao Liu
    Chinese Journal of Cancer, 2016, 35 (11) : 571 - 573
  • [9] A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
    Pang, Xiufeng
    Liu, Mingyao
    CHINESE JOURNAL OF CANCER, 2016, 35 : 92
  • [10] Targeting KRAS mutant non-small cell lung cancer (NSCLC) with deltarasin: A small molecule inhibitor of KRAS-PDEδ interaction.
    Zhang, Jun
    Xu, Ke
    Shin, Dong Moon
    Deng, Xingming
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345